DARZALEX® (daratumumab) receives positive CHMP opinion for treatment of MM
Janssen-Cilag announced the CHMP of the EMA has recommended broadening the existing marketing authorisation for DARZALEX® (daratumumab). If approved, daratumumab can be used in combination with lenalidomide and dexamethasone; or bortezomib and dexamethasone, for treatment of adult patients with MM. February 24, 2017